TICKERNERD
Menu
ILMNILMNHealthcare · Diagnostics & Research

ILMN Stock Forecast: Illumina, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$191
−0.91% on the day

The 20 Wall Street analysts covering Illumina, Inc. hold a median 12-month price target of $211 — +10.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$28.8B
Ticker Nerd rank
96 / 100
Median analyst target
$211
Analysts covering
20
Total return, dividends reinvested
1W
+1.6%
1M
−0.2%
YTD
+45.5%
1Y
+90.7%
From 52W high
−6.9%
From 52W low
+109.8%
$91
$205
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ILMN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Illumina, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Revisions
94
Momentum
94
Issuance
91
Value
88
Volatility
75
Accruals
44
Growth
42
Size
8

Quality (98): The business earns solid, repeatable profits on what it owns.

Growth (42): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ILMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ILMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200Oct 25Jan 26Apr 26Jul 26ILMNHigh $230Median $211Low $113

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says20 analysts
10 Buy6 Hold4 Sell
Low $113Median $211High $230

The green dot is the last close — the median target sits +10.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Aug 2026Canaccord GenuityMaintainsHold$190 → $205
3 Aug 2026CitigroupMaintainsSell$95 → $113
3 Aug 2026Piper SandlerReiteratesOverweight$200 → $225
31 July 2026BarclaysMaintainsUnderweight$145 → $160
31 July 2026GuggenheimMaintainsBuy$200 → $226
31 July 2026JP MorganMaintainsOverweight$220 → $230
31 July 2026RBC CapitalMaintainsOutperform$170 → $230
31 July 2026StifelMaintainsBuy$155 → $225
31 July 2026TD CowenMaintainsHold$192 → $210
17 July 2026Leerink PartnersMaintainsOutperform—
17 July 2026Leerink PartnersMaintainsOutperform$175 → $210
14 July 2026Canaccord GenuityMaintainsHold$140 → $190
14 July 2026Canaccord GenuityMaintainsHold—
6 July 2026Evercore ISI GroupMaintainsOutperform—
1 July 2026Piper SandlerMaintainsOverweight—
29 June 2026GuggenheimMaintainsBuy—
26 June 2026BernsteinReinstatesMarket Perform$185
24 June 2026BarclaysMaintainsUnderweight—
10 June 2026JP MorganUpgradeOverweight—
1 June 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ILMN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ILMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.6%
Analysts raising
2
Analysts cutting
1
Fundamentals

Illumina, Inc. (ILMN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.6×

Cheaper than 23% of US stocks

Price / sales
6.4×

Cheaper than 21% of US stocks

Price / book
10.2×

Cheaper than 11% of US stocks

EV / EBITDA
26.1×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
9.4%

Higher than 51% of US stocks

Earnings growth (YoY)
−11.9%

Higher than 24% of US stocks

Gross margin
66.1%

Higher than 80% of US stocks

Operating margin
21.1%

Higher than 80% of US stocks

Net margin
18.3%

Higher than 81% of US stocks

Returns & dividend
Return on equity
32.3%

Higher than 89% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ILMN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
ILMNIllumina, Inc.$28.8B
96
MTDMettler-Toledo International, Inc.$29.0B
92
LHLabcorp Holdings, Inc.$26.4B
86
DGXQuest Diagnostics, Inc.$26.1B
94
IQVIQVIA Holdings, Inc.$39.0B
92
WATWaters Corp.$40.4B
49
AAgilent Technologies, Inc.$42.1B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Illumina, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ILMN news & analysis

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Zacks Investment Research · 12 Aug 2026neutral

Zacks Investment Research compares BioMarin Pharmaceutical (BMRN) and Illumina (ILMN) as potential value options within the Medical - Biomedical and Genetics sector, examining which of the two companies might be the better choice for investors seeking undervalued stocks.

Why it matters — The article highlights Illumina's position as a potential value option among biomedical and genetics stocks, which is relevant for those tracking the company.

Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?

Zacks Investment Research · 12 Aug 2026positive

Zacks Investment Research highlights Illumina (ILMN) as a top-ranked growth stock, based on its Zacks Style Scores feature from the Zacks Premium research service. The item presents ILMN as a strong stock for investors using Zacks' growth-focused screening criteria.

Why it matters — ILMN watchers would care because the item signals that the stock scores well on Zacks' growth-style criteria, potentially supporting interest in the company's growth profile.

Diamond Hill Mid Cap Fund Q2 2026 Contributors And Detractors

Seeking Alpha · 11 Aug 2026positive

In its Q2 2026 commentary, Diamond Hill Mid Cap Fund reported strong equity market returns supported by corporate earnings and a resilient economy. Illumina was listed as a key contributor to the fund's performance during the quarter.

Why it matters — This indicates that Illumina was a positive performer within a major mid-cap fund during the second quarter of 2026.

What Makes Illumina (ILMN) a New Strong Buy Stock

Zacks Investment Research · 7 Aug 2026positive

Illumina (ILMN) was upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. The report notes this upgrade might drive the stock higher in the near term.

Why it matters — For ILMN watchers, the upgrade signals a more positive earnings outlook that could support near-term share performance.

Here's Why Illumina (ILMN) is a Strong Momentum Stock

Zacks Investment Research · 6 Aug 2026positive

Zacks Investment Research highlighted Illumina (ILMN) as a strong momentum stock, referencing its Style Scores system for identifying market-beating stocks.

Why it matters — ILMN watchers would care because the stock is being flagged by Zacks as having strong momentum, a factor its Style Scores system uses to identify potentially market-beating performers.

FAQ

Frequently asked questions about ILMN stock

What is the ILMN stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Illumina, Inc. have a median 12-month price target of $211, with estimates ranging from $113 to $230. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ILMN stock a buy right now?

Of the 20 analysts covering Illumina, Inc., 10 rate it a Buy, 6 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Illumina, Inc. 96 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ILMN?

As at 15 Aug 2026, Illumina, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will ILMN stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +10.5% from the last close, and Ticker Nerd's factor model ranks Illumina, Inc. 96 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ILMN stock forecast for 2030?

No analyst covering Illumina, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ILMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $113 to $230 over the next 12 months.

How has ILMN stock performed over the past year?

Illumina, Inc. returned +90.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Illumina, Inc. do?

Illumina, Inc. is a life sciences and diagnostics company that develops, manufactures, and markets tools and integrated systems for the analysis of genetic material.

What is the latest news on ILMN?

The most recent item we track (Zacks Investment Research, 12 Aug 2026): "BMRN vs. ILMN: Which Stock Is the Better Value Option?". Zacks Investment Research compares BioMarin Pharmaceutical (BMRN) and Illumina (ILMN) as potential value options within the Medical - Biomedical and Genetics sector, examining which of the two companies might be the better choice for investors seeking undervalued stocks.

Company

About Illumina, Inc.

Illumina, Inc. is a life sciences and diagnostics company that develops, manufactures, and markets tools and integrated systems for the analysis of genetic material. Its primary focus is on next-generation sequencing technologies, providing high-throughput and lower-throughput sequencing instruments, consumables, and related services used across research, clinical, and applied markets. Illumina’s platforms enable applications such as whole-genome sequencing, targeted sequencing, and genetic screening in areas including oncology, rare disease, reproductive health, infectious disease, and agriculture. The company also offers microarray products for cost-effective, focused genetic analysis, along with software, bioinformatics, and cloud-based tools that support data processing and interpretation. In addition, Illumina provides sequencing and microarray services, instrument monitoring, training, and consulting to laboratories and institutions worldwide. Founded in 1998 and headquartered in San Diego, California, Illumina plays a central role in enabling genomic research and clinical diagnostics by supplying core infrastructure that underpins many modern genomics applications.

CEO Mr. Jacob Thaysen Ph.D. · 8,600 employees · United States · https://www.illumina.com